We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HNRG:NASDAQHallador Energy Company Analysis

Data as of 2026-05-20 - not real-time

$17.38

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Hallador Energy (HNRG) trades at $17.38, just below its 20‑day SMA of $17.46 and slightly above the 50‑day SMA of $16.81, indicating a marginal short‑term pullback. The RSI sits at 48.8, suggesting the stock is neither oversold nor overbought, while the MACD histogram is negative and the signal line is bearish, pointing to limited upside momentum in the near term. Technical analysis shows a solid support level at $15.12 and a resistance ceiling near $22.40, with decreasing volume and a 30‑day volatility of over 60%, underscoring heightened price swings. Fundamentally, revenue has contracted 13.5% year‑over‑year, operating margins are negative, yet the company posted a modest profit margin of 5% and generated $9.86 M of free cash flow. The trailing PE of 32.8 far exceeds the industry average of 21.8, while the forward PE of 14.5 hints at earnings improvement, especially after the announced $1 B‑plus 12‑year capacity agreement pending regulator approval. However, the DCF‑derived fair value of $3.36 implies the market price is dramatically overvalued, a view reinforced by the 66% downside estimate. The balance sheet is relatively clean with low debt ($6.2 M) and a debt‑to‑equity ratio of 3.0, but the lack of dividends and a high beta of 1.12 add risk. Analyst consensus is a “strong buy,” yet the dilution concerns and earnings quality highlighted in recent earnings calls temper enthusiasm. Overall, HNRG sits at a crossroads: substantial long‑term contracted revenue potential versus current overvaluation and sector headwinds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and decreasing volume
  • Proximity to near‑term support at $15.12
  • High short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Pending $1 B 12‑year capacity agreement
  • Forward PE compression to 14.5
  • Continued sector and regulatory uncertainty

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑term contracted revenue stream
  • Low leverage and positive free cash flow
  • Potential upside if regulatory approval is secured

Key Metrics & Analysis

Financial Health

Revenue Growth-13.50%
Profit Margin4.98%
P/E Ratio32.8
ROE14.07%
ROA5.96%
Debt/Equity3.02
P/B Ratio4.8
Op. Cash Flow$63.2M
Free Cash Flow$9.9M
Industry P/E21.8

Technical Analysis

TrendNeutral
RSI48.8
Support$15.12
Resistance$22.40
MA 20$17.46
MA 50$16.81
MA 200$18.64
MACDBearish
VolumeDecreasing
Fear & Greed Index90.25

Valuation

Fair Value$3.36
Target Price$29.00
Upside/Downside66.86%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.12
Volatility60.52%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.